drugset / Trial / NCT04495257
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.
Timeline
- Start
- 2020-09-14
- Primary completion
- 2026-03-04
- Completion
- 2026-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | sotigalimab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | sotigalimab | Monoclonal antibody | 0.3 mg/kg | Intravenous |